Q-omics provides the consensus-scored COL5A3 profile across patient tissues and cancer cell-line models. COL5A3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, COL5A3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, COL5A3 protein abundance shows 19,656 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, KIRC, and BRCA as cancer lineages where COL5A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL5A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL5A3 survival associations across molecular data types. COL5A3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL5A3 RNA expression–survival associations across cancer types. High COL5A3 expression shows unfavorable associations in KIRP, UVM, ACC, BLCA, MESO and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for COL5A3 RNA expression.
This table summarizes COL5A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COL5A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL5A3 shows higher tumor expression in KIRC, HNSC, COAD, STAD, LIHC and BLCA. The KIRC box plot shows higher COL5A3 RNA expression in tumor versus normal tissue (log2 FC = +2.978, t-test p < 0.001).
This table shows molecular features associated with COL5A3 in patient tissues and cancer cell lines. In patient samples, COL5A3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, COL5A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
